Hypertension

A single patient, three antihypertensives in and still uncontrolled. The disagreement isn't about which fourth drug is best in general — it's about which one this particular kidney, and this particular job, can actually tolerate.

A single patient whose chart still reads "ACE-inhibitor allergy." Her hypertension and her rising proteinuria both indicate a renin-angiotensin-system blocker. The disagreement isn't about a second patient's different course — it's about whether a drug that spares the enzyme her original reaction depended on is close enough to trust.

Two women carry the same diagnosis into the same trimester from different starting points. One is already on a drug that's safe to keep and the only question is how tightly to control it. The other is already exposed to a drug that wasn't, and nothing about today's visit can undo that.

A newly hypertensive patient also lives with migraine with aura, and the antihypertensive with the strongest evidence for treating both conditions carries a theoretical neurological risk that some clinicians take seriously and others do not.

A woman with thirty years of mild, ulcer-free Raynaud's phenomenon needs a beta-blocker to help close a persistent blood-pressure gap and control a worsening tremor — but a nonselective agent carries a real, imperfectly-quantified risk of triggering the kind of vasospasm episode she has not had in three decades.

Confirmed sustained hypertension in a nationally-ranked competitive pistol shooter, whose sport bans beta-blockers at all times, in and out of competition. The real reason to avoid one turns out to have little to do with the ban itself.

Bilateral swelling on maximal-dose amlodipine, uncomfortable enough to change her daily life. The reflexive fix is a diuretic — the actual mechanism calls for something that works differently.

A second antihypertensive add-on where the kidney-protective choice and the cardiac-safety check point toward the same drug — once one number, not yet in the chart, gets confirmed.

He almost didn't bring it up. Once he did, the actual pharmacology turned out to matter: not every beta-blocker affects this the same way.

Her blood pressure chart looks like ordinary resistant hypertension, the kind that usually earns a beta-blocker without much debate. The diagnosis underneath it makes that same reflexive choice dangerous.

Chlorthalidone is usually the textbook next step for hypertension like his. His own gout history is the specific, personal reason that textbook step isn't automatically the right one for him.

A single patient whose new hypertension diagnosis surfaces within a medication regimen that has taken years to get right for an entirely different reason.

A single patient whose blood pressure is drifting upward as she approaches delivery, with two reasonable next steps and very little time left to see which one works.

A resistant-hypertension workup turned up biochemically confirmed primary aldosteronism and an adrenal nodule that imaging alone can't confirm is the actual source. The disagreement is about whether to find out for certain before treating, or to treat now regardless.

A severely elevated blood pressure, found incidentally in a patient with no symptoms and no evidence of acute organ damage, pulls two reasonable instincts in opposite directions: treat the number, or treat the patient in front of it.